Scarica l'app Stockscreener
1.35
1.50%
0.02
Dopo l'orario di chiusura:
1.37
0.02
+1.48%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.33
Aprire:
$1.35
Volume 24 ore:
727.57K
Relative Volume:
0.61
Capitalizzazione di mercato:
$92.30M
Reddito:
$525.00K
Utile/perdita netta:
$-44.76M
Rapporto P/E:
-2.0295
EPS:
-0.6652
Flusso di cassa netto:
$-37.46M
1 W Prestazione:
+3.85%
1M Prestazione:
-12.34%
6M Prestazione:
-52.96%
1 anno Prestazione:
-66.83%
Intervallo 1D:
$1.3049
$1.43
Intervallo di 1 settimana:
$1.23
$1.43
Portata 52W:
$1.16
$4.555
Cardiff Oncology Inc Stock (CRDF) Company Profile
Nome
Cardiff Oncology Inc
Settore
Industria
Telefono
858-952-7570
Indirizzo
11055 FLINTKOTE AVENUE, SAN DIEGO, CA
Compare CRDF vs VRTX, REGN, ARGX, RVMD, ALNY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRDF
Cardiff Oncology Inc
|
1.35 | 90.93M | 525.00K | -44.76M | -37.46M | -0.6652 |
VRTX
Vertex Pharmaceuticals Inc
|
480.25 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
663.09 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
876.25 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
183.95 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
288.06 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-05 | Iniziato | Noble Capital Markets | Outperform |
| 2025-07-08 | Iniziato | Ladenburg Thalmann | Buy |
| 2025-06-24 | Iniziato | Jefferies | Hold |
| 2024-09-06 | Iniziato | Craig Hallum | Buy |
| 2022-01-05 | Iniziato | William Blair | Outperform |
| 2021-12-08 | Iniziato | Robert W. Baird | Outperform |
| 2021-08-09 | Ripresa | Maxim Group | Buy |
| 2020-10-22 | Iniziato | H.C. Wainwright | Buy |
| 2020-10-08 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Cardiff Oncology Inc Borsa (CRDF) Ultime notizie
Enterprise value to EBIT forward of Cardiff Oncology, Inc. – FWB:XE7C - TradingView
CRDF Q1 2026 Earnings: EPS Miss Sends Mixed Signals Despite Modest Stock GainPerformance Review - dars.gov.et
Cardiff Oncology (CRDF) Noble Capital Markets Emerging Growth Virtual Investor Conference summary - Quartr
Price to earnings forward of Cardiff Oncology, Inc. – NASDAQ:CRDF - TradingView
Price to earnings forward of Cardiff Oncology, Inc. – TRADEGATE:XE7C - TradingView
Enterprise value to EBIT forward of Cardiff Oncology, Inc. – TRADEGATE:XE7C - TradingView
Price to book forward of Cardiff Oncology, Inc. – NASDAQ:CRDF - TradingView
CRDFCardiff Oncology Inc Dividends - Finviz
Is Cardiff Oncology, Inc. (CRDF) Stock Undervalued Amid Legal Uncertainty and Future Cancer Drug Potential? - Yahoo Finance
Cardiff Oncology, Inc.(NasdaqCM:CRDF) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com
Cardiff Oncology, Inc.(NasdaqCM: CRDF) dropped from Russell 2500 Growth Benchmark - marketscreener.com
Cardiff Oncology, Inc.(NasdaqCM: CRDF) dropped from Russell 2000 Value Benchmark - marketscreener.com
Cardiff Oncology, Inc.(NasdaqCM: CRDF) dropped from Russell 2000 Dynamic Index - marketscreener.com
Cardiff Oncology, Inc.(NasdaqCM:CRDF) dropped from Russell Small Cap Completeness Index - marketscreener.com
Cardiff Oncology, Inc.(NasdaqCM: CRDF) dropped from Russell 2500 Index - marketscreener.com
Cardiff Oncology, Inc.(NasdaqCM: CRDF) dropped from Russell 3000 Index - marketscreener.com
Cardiff Oncology, Inc.(NasdaqCM: CRDF) dropped from Russell 2000 Index - marketscreener.com
Cardiff Oncology, Inc.(NasdaqCM: CRDF) dropped from Russell 2000 Growth Benchmark - marketscreener.com
Cardiff Oncology, Inc.(NasdaqCM: CRDF) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Cardiff Oncology, Inc.(NasdaqCM: CRDF) dropped from Russell 3000E Value Benchmark - marketscreener.com
Cardiff Oncology, Inc.(NasdaqCM: CRDF) dropped from Russell 3000 Growth Benchmark - marketscreener.com
Cardiff Oncology | 4: Statement of changes in beneficial ownership of securities-Director TANNENBAUM RENEE P - Moomoo
Cardiff Oncology | 4: Statement of changes in beneficial ownership of securities-Director PACE GARY W - Moomoo
Cardiff Oncology, Inc. Actuals & Estimates (NASDAQ:CRDF) - TradingView
Cardiff Oncology, Inc. Actuals & Estimates (FWB:XE7C) - TradingView
Cardiff Oncology Inc (CRDF) Institutional Confidence - TradingKey
Cardiff Oncology, Inc. Actuals & Estimates (LS:A2P4GU) - TradingView
CRDF Forecast — Price Target — Prediction for 2027 - TradingView
CRDF Q1 2026 Earnings: EPS Misses Estimates as Clinical Progress Remains FocusLong-Term Guidance - dars.gov.et
CRDF News | CARDIFF ONCOLOGY INC (NASDAQ:CRDF) - ChartMill
Cardiff Oncology Inc (CRDF) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Daily Brief Health Care: Abbvie Inc, Blueprint Medicines, Cardiff Oncology, Fusion Antibodies , Guangdong True Health Medical Technology Development, High Tide , Nasos Pharma, Teladoc Health, Inc. and more - Smartkarma
Cardiff Oncology director Gary Pace buys $36,600 in stock By Investing.com - Investing.com Australia
CRDF: Phase II Update; Survival Advantage Extended - scr.zacks.com
Cardiff Oncology director Gary Pace buys $36,600 in stock - Investing.com UK
Insider Buying: Mani Mohindru Acquires Shares of Cardiff Oncology Inc (CRDF) - GuruFocus
Cardiff Oncology CEO Mani Mohindru buys $29,890 in company stock By Investing.com - Investing.com Nigeria
Cardiff Oncology CEO Mani Mohindru buys $29,890 in company stock - Investing.com
Form 4 Cardiff Oncology Inc For: 22 June By Investing.com - Investing.com Nigeria
Cardiff Oncology (CRDF) director Gary W. Pace buys 30,000 shares in open market - Stock Titan
Cardiff Oncology (CRDF) CEO makes open-market buy of 24,703 shares - Stock Titan
Cardiff Oncology (CRDF) Stifel 2025 Healthcare Conference Summary - Quartr
Cardiff Oncology (CRDF) Proxy filing Summary - Quartr
Cardiff Oncology Inc (CRDF) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cardiff Oncology Inc (CRDF) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cardiff Oncology Inc (CRDF) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cardiff Oncology Inc (CRDF) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cardiff Oncology Inc (CRDF) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cardiff Oncology Inc (CRDF) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cardiff Oncology Inc (CRDF) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cardiff Oncology (CRDF) director receives 40,565 stock options at $1.59 strike - Stock Titan
Cardiff Oncology Inc Azioni (CRDF) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Cardiff Oncology Inc Azioni (CRDF) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| PACE GARY W | Director |
Jun 18 '26 |
Buy |
1.22 |
30,000 |
36,600 |
1,356,376 |
| PACE GARY W | Director |
Jul 30 '25 |
Buy |
2.45 |
275,000 |
673,750 |
1,330,676 |
| PACE GARY W | Director |
Jul 30 '25 |
Buy |
2.45 |
15,000 |
36,750 |
1,345,676 |
5.60%
0.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):